Combined Therapy of Deoxyspergualin and Plasmapheresis: A Useful Treatment for Antibody-Mediated Acute Rejection After Kidney Transplantation

Nojima, Masanori; Yoshimoto, T; Nakao, Atsunori; Maruyama, Takuo; Takiuchi, Hidekazu; Mataga, Izumi; Hashimoto, Mitsuo; Kyo, Masahiro; Shima, Hiroki

doi:10.1016/j.transproceed.2004.12.251

Cited by 13 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accord with the literature [2,3], in our observations, the 2 extracorporeal procedures had similar effects in terms of graft survival, DSA removal, and cross-match negativity (group A 74% vs 86%; 95% vs 100%). IA was faster to remove DSA than DFPP (negative values; 18 vs 25 days) [4]. The only case in group A with no DSA negativity was anuric at the time of starting treatment; which emphasizes the importance of a timely diagnosis and therapy.…”

Section: Discussionmentioning

confidence: 86%

Plasmapheresis, Photopheresis, and Endovenous Immunoglobulin in Acute Antibody-mediated Rejection in Kidney Transplantation

Pretagostini¹,

Poli²,

Gozzer

et al. 2015

Transplantation Proceedings

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 86%

Plasmapheresis, Photopheresis, and Endovenous Immunoglobulin in Acute Antibody-mediated Rejection in Kidney Transplantation

Pretagostini¹,

Poli²,

Gozzer

et al. 2015

Transplantation Proceedings

View full text Add to dashboard Cite

“…IA is a specific technique for removing isoagglutinins and is part of the ABO-I desensitisation protocol in most European centers at present [44]. IA can faster to remove DSA than DFPP [45], and compared to plasmapheresis, IA allows not only a more specific but also a more effective clearance of circulating immunoglobulins without the side effects associated with the substitution of FFP or albumin [46,47]. However, the higher costs associated with the use of IA indicates its use in high-risk populations (i.e., hyperimmune or ABO-I patients, pretransplantcross-match positivity, AAMR) [38].…”

Section: Discussionmentioning

confidence: 99%

Plasmapheresis Therapy in Kidney Transplant Rejection

et al. 2018

View full text Add to dashboard Cite

Kidney transplantation (KT) is considered an optimal treatment strategy for end-stage renal disease. But human leukocyte antigen-sensitized, ABO-incompatible and antibody-mediated rejection might be the alarming hurdles in KT. Therapeutic plasma exchange is the mainstay of the antibody reduction therapy for reducing autoantibody more effectively. Even in the treatment for highly sensitized patients, it has played an indispensable role. However, clinicians should tailor therapies to individual patient’s needs and multimodal treatment will bring better outcomes. Early diagnosis and precise treatment would reduce morbidity, mortality, and economic costs.

show abstract

“…Nojima et al reported on the use of DSG and PP in five living donor kidney recipients with AMR. There was resolution of AMR in four out of five patients (80%) [42]. The dose of DSG was 3 mg/kg/day for 10 days with PP of 1 --9 sessions depending on treatment outcome.…”

Section: Deoxyspergualinmentioning

confidence: 95%